These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35745812)

  • 1. The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease-A Systematic Literature Review.
    Wiersma TK; Visschedijk MC; de Boer NK; Lub-de Hooge MN; Prins JR; Touw DJ; Mian P
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.
    Ylisaukko-Oja T; Puttonen M; Jokelainen J; Koivusalo M; Tamminen K; Torvinen S; Voutilainen M
    Scand J Gastroenterol; 2022 Apr; 57(4):415-423. PubMed ID: 34927504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
    Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG
    Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
    Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
    Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review.
    van Gendt J; Emaus R; Visschedijk MC; Touw DJ; Bouwknegt DG; de Leeuw K; Prins JR; Malik P; Mian P
    Clin Pharmacokinet; 2024 May; 63(5):589-622. PubMed ID: 38583128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part III Non-penicillin and Non-cephalosporin Drugs.
    Groen F; Prins JR; Hooge MNL; Winter HLJ; Kosterink JGW; Touw DJ; Mian P
    Clin Pharmacokinet; 2023 Mar; 62(3):399-434. PubMed ID: 36940039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurine Metabolite Shunting in Late Pregnancy Increases the Risk of Intrahepatic Cholestasis of Pregnancy in Women With Inflammatory Bowel Disease, and Can be Managed With Split Dosing.
    Prentice R; Flanagan E; Wright E; Prideaux L; Connell W; Sparrow M; De Cruz P; Lust M; Hardikar W; Goldberg R; Vogrin S; Palmer K; Ross A; Burns M; Greeve T; Bell S
    J Crohns Colitis; 2024 Aug; 18(7):1081-1090. PubMed ID: 38366352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system.
    Wieringa JW; Driessen GJ; Van Der Woude CJ
    Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):811-818. PubMed ID: 29972674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
    Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
    Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
    Beswick L; Friedman AB; Sparrow MP
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
    Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review.
    Pariente G; Leibson T; Carls A; Adams-Webber T; Ito S; Koren G
    PLoS Med; 2016 Nov; 13(11):e1002160. PubMed ID: 27802281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease.
    Sparrow MP
    Gastroenterol Hepatol (N Y); 2008 Jul; 4(7):505-11. PubMed ID: 21960930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiopurine pharmacogenomics and pregnancy in inflammatory bowel disease.
    Andoh A; Kawahara M; Imai T; Tatsumi G; Inatomi O; Kakuta Y
    J Gastroenterol; 2021 Oct; 56(10):881-890. PubMed ID: 34287682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Wils P; Seksik P; Stefanescu C; Nancey S; Allez M; Pineton de Chambrun G; Altwegg R; Gilletta C; Vuitton L; Viennot S; Serrero M; Fumery M; Savoye G; Collins M; Goutorbe F; Brixi H; Bouguen G; Tavernier N; Boualit M; Amiot A; Abitbol V; Laharie D; Pariente B;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):460-470. PubMed ID: 33345331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight and Body Composition Compartments do Not Predict Therapeutic Thiopurine Metabolite Levels in Inflammatory Bowel Disease.
    Holt DQ; Strauss BJ; Moore GT
    Clin Transl Gastroenterol; 2016 Oct; 7(10):e199. PubMed ID: 27787512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
    Khan N; Asim H; Lichtenstein GR
    Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.